ERBB2 and breast cancer: A median of 20% triple-negative (TNBC), 16% HER2+, and 6% ER+/PR+/HER2- (HR+) breast cancers show predominant lymphocyte infiltration (defined as >50% lymphocytic infiltrate) [36].